NYSE:NKGN NKGen Biotech (NKGN) Stock Price, News & Analysis $0.16 +0.00 (+1.55%) As of 03/28/2025 03:46 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About NKGen Biotech Stock (NYSE:NKGN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get NKGen Biotech alerts:Sign Up Key Stats Today's Range$0.15▼$0.2150-Day Range$0.14▼$0.8452-Week Range$0.10▼$2.19Volume185,563 shsAverage Volume1.90 million shsMarket Capitalization$7.34 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewNKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.Read More… Remove Ads Receive NKGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NKGen Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address NKGN Stock News HeadlinesNKGen Biotech to Present Phase 1 Results on Troculeucel NK Cell Therapy for Alzheimer's at AD/PD™ 2025 ConferenceMarch 27 at 11:00 AM | nasdaq.comNKGen Biotech To Present Updated Troculeucel Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2025)March 25, 2025 | markets.businessinsider.comElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest breakthrough in artificial intelligence… but in human technology. It’s so valuable that some are referring to it as the “new gold”.March 29, 2025 | True Market Insiders (Ad)NKGen Biotech To Present Updated Troculeucel Data at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD™ 2025)March 25, 2025 | globenewswire.comNKGen Biotech moving to OTC Markets, cancels 1-for-6 reverse stock splitMarch 4, 2025 | markets.businessinsider.comNKGen Biotech, Inc. to Transition from the Nasdaq Global Market to OTC Markets; Reverse Stock Split will not be ImplementedMarch 4, 2025 | globenewswire.comNKGen Biotech announces administration of first dose of troculeucelMarch 3, 2025 | markets.businessinsider.comNKGen Biotech Announces Administration of First Dose of Troculeucel to Stroke Patient Under FDA-Cleared Compassionate Use ProgramMarch 3, 2025 | globenewswire.comSee More Headlines NKGN Stock Analysis - Frequently Asked Questions How have NKGN shares performed this year? NKGen Biotech's stock was trading at $0.6552 at the beginning of the year. Since then, NKGN shares have decreased by 75.1% and is now trading at $0.1633. View the best growth stocks for 2025 here. Who are NKGen Biotech's major shareholders? Top institutional shareholders of NKGen Biotech include Polar Asset Management Partners Inc. (1.11%), Polar Asset Management Partners Inc. (1.11%), Magnetar Financial LLC (0.60%) and Kepos Capital LP (0.51%). Insiders that own company stock include Paul Y Song and James A Graf. View institutional ownership trends. How do I buy shares of NKGen Biotech? Shares of NKGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of NKGen Biotech own? Based on aggregate information from My MarketBeat watchlists, some other companies that NKGen Biotech investors own include Meta Platforms (META), IonQ (IONQ), Eli Lilly and Company (LLY), NVIDIA (NVDA), Viking Therapeutics (VKTX), Adaptimmune Therapeutics (ADAP) and C3.ai (AI). Company Calendar Today3/29/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNYSE:NKGN Previous SymbolNYSE:NKGN CIK1845459 Webnkgenbiotech.com Phone949-396-6830FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-82,940,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-479.36% Debt Debt-to-Equity RatioN/A Current Ratio0.02 Quick Ratio0.02 Sales & Book Value Annual Sales$80,000.00 Price / Sales91.75 Cash FlowN/A Price / Cash FlowN/A Book Value($2.68) per share Price / Book-0.06Miscellaneous Outstanding Shares44,948,000Free Float40,291,000Market Cap$7.34 million OptionableNot Optionable Beta0.45 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NYSE:NKGN) was last updated on 3/29/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy sharehold...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NKGen Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NKGen Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.